Literature DB >> 19390299

Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities.

Linda Simoni-Wastila1, Priscilla T Ryder, Jingjing Qian, Ilene H Zuckerman, Thomas Shaffer, Lirong Zhao.   

Abstract

OBJECTIVE: Antipsychotic (AP) utilization has grown significantly in long-term care (LTC) settings. Although a growing literature associates AP use with higher mortality in elderly with dementia, the association of APs with hospital events is unclear. The authors examine prevalence and trends in AP use by Medicare beneficiaries residing in LTC and the association of APs and other drug use variables with hospital events and mortality.
DESIGN: Retrospective analysis using sequential multivariate Cox proportional hazards models.
SETTING: Medicare Current Beneficiary Survey linked to Institutional Drug Administration and Minimum Data Set files. PARTICIPANTS: A total of 2,363 LTC Medicare beneficiaries, 1999-2002. MEASUREMENTS: Trends in LTC AP use overall and by type and duplicative use; association of AP utilization and two outcomes: hospital events and all-cause mortality.
RESULTS: AP use rose markedly from 1999 to 2002 (26.4%-35.9%), predominantly due to increased use of atypical agents. After controlling for sociodemographic and clinical factors, AP use is not related to hospital events (hazard ratio [HR] = 0.98, 95% confidence interval [CI] = 0.82-1.63 p = 0.7951). AP use is associated with reduced mortality in unadjusted and intermediate models, but loss of significance in the final model (HR = 0.83, 95% CI = 0.69-1.00, p = 0.0537) suggests that disease and drug burden factors may confound the AP-mortality relationship.
CONCLUSION: This study provides no evidence of increased hospital events or mortality in LTC residents who use AP medications. Findings contribute to a growing body of evidence that APs, particularly atypical agents, may be associated with reduced mortality in LTC residents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390299      PMCID: PMC3773714          DOI: 10.1097/JGP.0b013e31819b8936

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  24 in total

1.  Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients.

Authors:  Mitchell J Barnett; Paul J Perry; Bruce Alexander; Peter J Kaboli
Journal:  J Clin Psychopharmacol       Date:  2006-04       Impact factor: 3.153

2.  Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest.

Authors:  Rosa Liperoti; Giovanni Gambassi; Kate L Lapane; Claire Chiang; Claudio Pedone; Vincent Mor; Roberto Bernabei
Journal:  Arch Intern Med       Date:  2005-03-28

3.  Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.

Authors:  Guk-Hee Suh; Ajit Shah
Journal:  Int Psychogeriatr       Date:  2005-09       Impact factor: 3.878

4.  The quality of antipsychotic drug prescribing in nursing homes.

Authors:  Becky A Briesacher; M Rhona Limcangco; Linda Simoni-Wastila; Jalpa A Doshi; Suzi R Levens; Dennis G Shea; Bruce Stuart
Journal:  Arch Intern Med       Date:  2005-06-13

5.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

Authors:  Lon S Schneider; Karen Dagerman; Philip S Insel
Journal:  Am J Geriatr Psychiatry       Date:  2006-03       Impact factor: 4.105

6.  How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience.

Authors:  Carolyn S Dewa; Gary Remington; Nathan Herrmann; Joan Fearnley; Paula Goering
Journal:  Clin Ther       Date:  2002-09       Impact factor: 3.393

7.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Authors:  Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

8.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

9.  Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.

Authors:  Rajender R Aparasu; Elda Jano; Michael L Johnson; Hua Chen
Journal:  Am J Geriatr Pharmacother       Date:  2008-10

10.  A profile of the Medicare Current Beneficiary Survey.

Authors:  G S Adler
Journal:  Health Care Financ Rev       Date:  1994
View more
  22 in total

1.  Pharmacotherapy for late-life depression.

Authors:  George S Alexopoulos
Journal:  J Clin Psychiatry       Date:  2011-01       Impact factor: 4.384

2.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

3.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

4.  Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.

Authors:  Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Richard Hansen
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

Review 5.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 6.  A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia.

Authors:  Maryse Lapeyre-Mestre
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

Review 7.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

8.  Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Authors:  D P Devanand; Jacobo Mintzer; Susan K Schultz; Howard F Andrews; David L Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Bruce Levin
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

9.  Pharmacotherapeutic management of dementia across settings of care.

Authors:  Gail B Rattinger; Mehmet Burcu; Sarah K Dutcher; Pankdeep T Chhabra; Paul B Rosenberg; Linda Simoni-Wastila; Christine S Franey; Loreen D Walker; Ilene H Zuckerman
Journal:  J Am Geriatr Soc       Date:  2013-04-16       Impact factor: 5.562

Review 10.  Medications and Prescribing Patterns as Factors Associated with Hospitalizations from Long-Term Care Facilities: A Systematic Review.

Authors:  Kate N Wang; J Simon Bell; Esa Y H Chen; Julia F M Gilmartin-Thomas; Jenni Ilomäki
Journal:  Drugs Aging       Date:  2018-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.